Changes in Alcohol-Related Behaviors and Quality of Life During the COVID-19 Pandemic: Impact of Alcohol Use Disorder Diagnosis and Treatment History

J Clin Psychiatry 2023;84(1):22br14462

To cite: Luk JW, Stangl BL, Gunawan T, et al. Changes in alcohol-related behaviors and quality of life during the COVID-19 pandemic: impact of alcohol use disorder diagnosis and treatment history. J Clin Psychiatry. 2023;84(1):22br14462.
To share: https://doi.org/10.4088/JCP.22br14462

© 2022 Physicians Postgraduate Press, Inc.

^aOffice of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
^bHuman Psychopharmacology Laboratory, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
^cSection of Sensory Science and Metabolism, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
^dClinical NeuroImaging Research Core, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
^eLaboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, Rockville, Maryland
‡Equal contribution.
*Corresponding authors: Jeremy W. Luk, PhD, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Office of the Clinical Director, Bldg 10 – CRC, Room 1-5340, Bethesda, MD 20892 ([email protected]); Vijay A. Ramchandani, PhD, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Human Psychopharmacology Laboratory, Bldg 10 – CRC, Room 2-2352, Bethesda, MD 20892 ([email protected]).

The COVID-19 pandemic has led to increases in anxiety and depression worldwide.¹ While mental health challenges and pandemic-related stress may trigger alcohol drinking to cope,² there is substantial heterogeneity in changes in drinking patterns from before to during the pandemic.³ Individuals with a history of alcohol use disorder (AUD) may be vulnerable to COVID-related complications and alcohol relapse.^4,5 We examined longitudinal changes in alcohol-related and quality of life (QoL) outcomes among individuals with AUD (separated by treatment history) and contrasted these time changes to those observed among healthy controls.

Methods

From June 3, 2020, to March 5, 2021, we reached out to 1,203 prior participants of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) Natural History Protocol. After excluding participants that (1) did not respond (n = 548); (2) declined/withdrew (n = 233); (3) completed the survey after March 11, 2021 (n = 23); and (4) had missing data on primary study variables (n = 21), 378 participants were enrolled in the NIAAA COVID-19 Pandemic Impact of Alcohol (C19-PIA) Study. Data were collected by phone and/or through an online survey. The study sample was 46.6% female, 52.7% White, 32.0% Black, and 15.3% Other Race. Most participants (91.0%) resided in Maryland (57.4%), Washington, DC (19.8%), or Virginia (13.8%). AUD diagnosis was determined to be positive in 163 participants (43.1%), using Structured Clinical Interview for DSM-IV or DSM-5, in the Natural History Protocol.⁶ Of these individuals, 109 underwent inpatient treatment at NIAAA. Based on history of AUD treatment status, we created 3 groups: “healthy control” (56.9%; n = 215, of which 36 were nondrinkers); “non-treatment AUD” (14.3%; n = 54); and “treatment AUD” (28.8%; n = 109). Of the 378 participants, 320 (84.7%) were asked to report alcohol craving and 293 (77.5%) also provided data on QoL. The study was approved by the National Institutes of Health Intramural Institutional Review Board.

Data mapping onto 3 timepoints were extracted from the Natural History Protocol (T1) and the C19-PIA Study (T2: retrospectively reported pre-pandemic timepoint; T3: timepoint during the pandemic). Time lapsed from T1 to C19-PIA Study (“cohort”) ranged from 28.8% < 1 year, 37.6% 1–2 years, and 33.6% 3–5 years. Participant enrollment was stratified into 3 phases: from June 3, 2020, to July 31, 2020 (27.8%); from August 1, 2020, to November 22, 2020 (37.0%); and from November 23, 2020, to March 5, 2021 (35.2%). Study outcomes included Alcohol Use Disorders Identification Test (AUDIT)⁷ for problematic drinking, Penn Alcohol Craving Scale⁸ for alcohol craving, and World Health Organization QoL-BREF⁹ for 4 QoL domains. Multilevel modeling was used to account for the nesting structure of observations across time within participants. The multilevel models tested interactions of time and AUD treatment status on study outcomes while adjusting for age, sex, race, cohort, and enrollment phase.

Results

Longitudinal changes in outcomes varied by AUD treatment status (Figure 1). Pairwise effects of time on outcomes are presented in Supplementary Table 1. Problematic drinking in the healthy control group remained low across time. Individuals with AUD regardless of treatment history scored lower on problematic drinking at T2 and T3 relative to T1. Despite these declines, AUDIT scores remained the highest in the treatment AUD group at T3 (mean = 15.0, SD = 13.2). Increases in alcohol craving from T1 to T3 were observed in the healthy control and treatment AUD groups. Alcohol craving in the non-treatment AUD group decreased from T1 to T2 and increased from T2 to T3. All 4 QoL domains in the healthy control group decreased across time. Similar declines were observed for most QoL domains in the non-treatment AUD group. QoL scores in the treatment AUD group were lowest at T1 and remained generally low across time.

Discussion

Relative to pre-pandemic levels, problematic drinking remained low among healthy controls and declined among individuals with a history of AUD during the pandemic. Reductions in AUDIT scores in the treatment AUD group may reflect potential beneficial effects of the NIAAA inpatient treatment program and/or more limited social opportunities for drinking during the pandemic.^10,11 However, despite within-group reductions, the average pandemic AUDIT score in this group was still above the clinical threshold (≥ 8), indicating the need for continued intervention.

Increases in alcohol craving in the healthy control and treatment-seeking AUD groups revealed an understudied dimension of drinking warranting surveillance. Fewer recreational and social activities along with higher COVID-related stress (eg, unemployment, losing a loved one, financial stress) may have contributed to QoL reductions among healthy controls.^12,13 Lack of change in QoL among individuals with AUD may reflect a floor effect given the initially low QoL levels.

Study limitations include a convenience regional sample limiting generalizability, attrition from Natural History Protocol, varied time lapsed from T1 to the C19-PIA Study, T2 retrospective report, partial data on QoL, and lack of AUD diagnostic and treatment data at T3. More research is needed to understand challenges individuals with AUD encountered during the pandemic (eg, social isolation, disruption to treatment) to inform approaches (eg, telemedicine) to support recovery from AUD.

Published online: November 7, 2022.
Relevant financial relationships: The authors have no conflicts of interest to disclose.
Funding/support: This study was supported by National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research (Z1A AA000130, Z1A AA000466) and a National Institute of Allergy and Infectious Diseases Intramural Targeted Anti-COVID (ITAC) Award.
Role of the sponsor: The sponsors funded the C19-PIA Study and had no role in the design, analysis, or interpretation of study findings.
Disclaimer: The content of this study is solely the responsibility of the authors.
Previous presentation: An earlier version of this study was presented virtually at the 2021 American Psychiatric Association Annual Meeting.
Acknowledgments: The authors thank Betsy Davis, Cheryl Jones, Samantha Fede, Alyssa Brooks, Tonette Vinson, Yvonne Horneffer, LaToya Sewell, the ClinDB IT team (Thuy Van, Etienne Lamoreaux, Denise Gates-Nee, Nancy Agarwal, Patty Bates, Jonathan Folkers), and the intrepid postbaccalaurate Intramural Research Training Award fellows (Hannah Kim, Noa Leiter, Emma McCabe, Carlos Melendez, Kurren Parida, Rhianna Vergeer, Ugne Ziausyte) for supporting the execution of the C19-PIA Study.
Trial registration: ClinicalTrials.gov identifier: NCT04391816
Supplementary material: Available at Psychiatrist.com.